Literature DB >> 15223083

Dose-response relationship between opioid use and adverse effects after ambulatory surgery.

Sean Z Zhao1, Frances Chung, David B Hanna, Anna L Raymundo, Raymond Y Cheung, Connie Chen.   

Abstract

This health outcomes analysis based on data from a randomized, double-blind, placebo-controlled trial determined dose-response relationship between opioid use and related symptoms. All patients received intravenous fentanyl on demand for pain predischarge, and oral acetaminophen 500 mg/hydrocodone 5 mg every 4-6 hours as needed postdischarge for up to 7 days postsurgery. Patients completed an opioid-related Symptom Distress Scale (SDS) questionnaire every 24 hours postdischarge for 7 days, which assessed 12 opioid-related symptoms by 3 ordinal measures: frequency, severity, and bothersomeness. Clinically meaningful events (CMEs) were defined based on the responses to this questionnaire. Opioid use was converted to morphine equivalent dose (MED). The dose-response relationship between composite SDS scores and MED on Day 1, on Days 0 and 1, and on Days 1-4, was assessed. SDS scores for all 12 symptoms within the 3 dimensions were significantly associated with MED on Day 1 (F-value=1.56; P=0.04), as well as cumulative MED used on Days 0 and 1 (F-value=1.85; P<0.01). Patients with a specific CME used a higher MED than those without a CME on Day 1 (P<0.001). Between Days 1 and 4, patients with a higher number of patient-CME-days used a significantly higher MED. Regression analyses suggested that once the MED reached a threshold, approximately every 4 mg increase in MED was related to 1 additional patient-CME-day (P<0.01). A dose-response relationship empirically exists between MED and directly assessed opioid-related CMEs after ambulatory laparoscopic cholecystectomy. Once daily MED reaches a threshold, every 3-4 mg increase will be associated with 1 additional clinically meaningful opioid-related symptom, or 1 additional patient-day with an opioid-related CME.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223083     DOI: 10.1016/j.jpainsymman.2003.11.001

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  30 in total

1.  [Postoperative pain management after ambulatory surgery. A survey of anaesthesiologists].

Authors:  E A Lux; U Stamer; W Meissner; A Wiebalck
Journal:  Schmerz       Date:  2011-04       Impact factor: 1.107

2.  Conflicting results in clinical research: is the proof in the P value, the study design, or the pudding?

Authors:  Brian M Ilfeld; Edward R Mariano; Joseph M Neal
Journal:  Reg Anesth Pain Med       Date:  2007 May-Jun       Impact factor: 6.288

Review 3.  [Combined analgesics for postoperative pain therapy. Review of effectivity and side-effects].

Authors:  H Lange; P Kranke; P Steffen; T Steinfeldt; H Wulf; L H J Eberhart
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

4.  [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].

Authors:  M Merker; G Dinges; T Koch; P Kranke; A M Morin
Journal:  Schmerz       Date:  2012-02       Impact factor: 1.107

5.  Effects of transcutaneous electrical acupoint stimulation at different frequencies on perioperative anesthetic dosage, recovery, complications, and prognosis in video-assisted thoracic surgical lobectomy: a randomized, double-blinded, placebo-controlled trial.

Authors:  Shun Huang; WenPing Peng; Xue Tian; Hansheng Liang; Zhe Jia; Theresa Lo; Miao He; Yi Feng
Journal:  J Anesth       Date:  2015-09-08       Impact factor: 2.078

6.  Cost analysis applied to postoperative analgesia regimens: a comparison between parecoxib and propacetamol.

Authors:  P Tilleul; H Weickmans; P Tan Sean; A Lienhart; M Beaussier
Journal:  Pharm World Sci       Date:  2007-02-20

7.  To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self-identified chronic pain patients.

Authors:  D Andrew Tompkins; Andrew S Huhn; Patrick S Johnson; Michael T Smith; Eric C Strain; Robert R Edwards; Matthew W Johnson
Journal:  Addiction       Date:  2017-08-10       Impact factor: 6.526

8.  Development and validation of a composite score based on clinically meaningful events for the opioid-related symptom distress scale.

Authors:  Kitty S Chan; Wen-Hung Chen; T J Gan; Ray Hsieh; Connie Chen; Mani Lakshminarayanan; Dennis A Revicki
Journal:  Qual Life Res       Date:  2009-10-30       Impact factor: 4.147

9.  Nausea, vomiting, sleep, and restfulness upon discharge home after outpatient anterior cruciate ligament reconstruction with regional anesthesia and multimodal analgesia/antiemesis.

Authors:  Brian A Williams; Michael L Kentor; James J Irrgang; Matthew T Bottegal; John P Williams
Journal:  Reg Anesth Pain Med       Date:  2007 May-Jun       Impact factor: 6.288

10.  Polymorphism of μ-Opioid Receptor Gene (OPRM1:c.118A>G) Might Not Protect against or Enhance Morphine-Induced Nausea or Vomiting.

Authors:  Li-Kuei Chen; Shiou-Sheng Chen; Chi-Hsiang Huang; Hong-Jyh Yang; Chen-Jung Lin; Kuo-Liong Chien; Shou-Zen Fan
Journal:  Pain Res Treat       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.